Understanding Biomarker Method Validation: The Critical Role of Parallelism

The January 2025 FDA Biomarker Assay Validation guidance suggests using PK validation approaches as a starting point. However, when it comes to dilutional linearity and parallelism, our extensive implementation experience reveals a fundamental scientific distinction that demands careful consideration.

Understanding Traditional Drug Assay Validation

In drug concentration assays, dilutional linearity serves as a cornerstone validation parameter. Analysts create a high-concentration sample by spiking their reference standard (the drug product) into matrix and demonstrate recovery through serial dilutions. This approach works precisely because the spiked material is identical to what they’ll measure in study samples – the same drug molecule in the same matrix.

The Scientific Challenge of Biomarker Assays

Biomarker measurement presents a fundamentally different scientific reality. Our experience bringing biomarkers through development to regulatory approval has revealed a crucial insight: dilutional linearity, by its very definition, requires spiked control samples using a true reference standard. Since biomarker assays typically use surrogate calibrator materials that differ from the endogenous molecule we need to measure, the traditional dilutional linearity approach becomes scientifically irrelevant.

The Critical Role of Parallelism

In biomarker validation, parallelism emerges as the scientifically sound approach for demonstrating reliable measurement. Through parallelism studies performed across multiple individuals, we:

• Establish the minimum required dilution (MRD) of the assay to ensure no non-specific matrix interference

• Establish the range of dilutions that enable reliable measurement of the endogenous analyte

• Demonstrate that our critical reagents recognize both calibrator material and endogenous analyte similarly

• Verify consistent measurement behavior across different biological samples and concentration ranges

Why This Matters

This shift from dilutional linearity to parallelism isn’t merely a technical preference – it reflects a deeper understanding of what we need to demonstrate for biomarker assays. We must show that our method reliably measures the endogenous molecule across its biological range and in its natural context.